BACKGROUND: It is believed that chemotherapy (ChT) is ineffective in papillary thyroid carcinoma (PTC). The aim of our retrospective chart review was to find out if neoadjuvant ChT before thyroid surgery had any effect on the size of primary tumors in patients with PTC. METHODS: The study included 16 patients (13 women, 3 men; median age 63.5 years) with PTC, who were treated with neoadjuvant ChT from 1988 to 2005. Poorly differentiated PTC, classical PTC, a follicular variant of PTC, and a Hürthle cell variant of PTC were diagnosed in 5, 5, 3, and 3 cases, respectively. The mean tumor diameter was 9.67 cm. Seven patients had a pT4 tumor. Regional and distant metastases were detected in 10 and 7 patients, respectively. ChT consisted of vinblastine in 11 cases, vinblastine with adriamycin in 2 cases, and other schedules in 3 cases. Four patients were also treated with preoperative external irradiation. RESULTS: Altogether, 40 cycles of ChT were given. After ChT, the tumor size decreased in all 16 patients: by >50% in 7 (44%) patients and by <50% in 9 patients. R0, R1, and R2 resection was performed in 2, 10, and 4 cases, respectively. The median survival time of our patients was 88 months. Six patients are still alive; two died of causes not related to carcinoma, while eight patients died of PTC. CONCLUSIONS: Neoadjuvant ChT before thyroid surgery may be effective in patients with locally advanced PTC. After neoadjuvant ChT, in 44% of patients, the tumor size decreased by >50%.
BACKGROUND: It is believed that chemotherapy (ChT) is ineffective in papillary thyroid carcinoma (PTC). The aim of our retrospective chart review was to find out if neoadjuvant ChT before thyroid surgery had any effect on the size of primary tumors in patients with PTC. METHODS: The study included 16 patients (13 women, 3 men; median age 63.5 years) with PTC, who were treated with neoadjuvant ChT from 1988 to 2005. Poorly differentiated PTC, classical PTC, a follicular variant of PTC, and a Hürthle cell variant of PTC were diagnosed in 5, 5, 3, and 3 cases, respectively. The mean tumor diameter was 9.67 cm. Seven patients had a pT4 tumor. Regional and distant metastases were detected in 10 and 7 patients, respectively. ChT consisted of vinblastine in 11 cases, vinblastine with adriamycin in 2 cases, and other schedules in 3 cases. Four patients were also treated with preoperative external irradiation. RESULTS: Altogether, 40 cycles of ChT were given. After ChT, the tumor size decreased in all 16 patients: by >50% in 7 (44%) patients and by <50% in 9 patients. R0, R1, and R2 resection was performed in 2, 10, and 4 cases, respectively. The median survival time of our patients was 88 months. Six patients are still alive; two died of causes not related to carcinoma, while eight patients died of PTC. CONCLUSIONS: Neoadjuvant ChT before thyroid surgery may be effective in patients with locally advanced PTC. After neoadjuvant ChT, in 44% of patients, the tumor size decreased by >50%.
Authors: Sheng-Yao Cheng; Alexander T H Wu; Gaber El-Saber Batiha; Ching-Liang Ho; Jih-Chin Lee; Halimat Yusuf Lukman; Mohammed Alorabi; Abdullah N AlRasheedi; Jia-Hong Chen Journal: Biology (Basel) Date: 2022-02-17
Authors: Rajan P Dang; Daniel McFarland; Valerie H Le; Nadia Camille; Brett A Miles; Marita S Teng; Eric M Genden; Krzysztof J Misiukiewicz Journal: Int J Surg Oncol Date: 2016-09-22
Authors: Carla Fernanda Nava; Rafael Selbach Scheffel; Ana Patrícia Cristo; Carla Vaz Ferreira; Shana Weber; André Borsatto Zanella; Francisco Costa Paixão; Alceu Migliavaca; José Ricardo Guimarães; Marcia Silveira Graudenz; José Miguel Dora; Ana Luiza Maia Journal: Front Endocrinol (Lausanne) Date: 2019-10-22 Impact factor: 5.555
Authors: José F Carrillo; Jesús Manuel Flores; Gilberto Espinoza; Rafael Vázquez-Romo; Margarita C Ramírez-Ortega; Liliana C Carrillo; Beatriz Y Cortés-García; Francisco J Ochoa-Carrillo; Luis F Oñate-Ocaña Journal: Front Oncol Date: 2021-01-19 Impact factor: 6.244